Vernalis plc (LON:VER) has been assigned an average recommendation of “Buy” from the five brokerages that are currently covering the company. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is GBX 77.25 ($0.94).
VER has been the subject of several recent analyst reports. Shore Capital restated a “house stock” rating on shares of Vernalis plc in a report on Tuesday, July 19th. Panmure Gordon restated a “buy” rating and issued a GBX 76 ($0.93) price target on shares of Vernalis plc in a report on Thursday, September 22nd. Canaccord Genuity lifted their price target on Vernalis plc from GBX 84 ($1.02) to GBX 88 ($1.07) and gave the company a “buy” rating in a report on Thursday, September 29th. Stifel Nicolaus restated a “buy” rating and issued a GBX 94 ($1.15) price target on shares of Vernalis plc in a report on Friday, July 8th. Finally, N+1 Singer restated a “hold” rating and issued a GBX 46 ($0.56) price target on shares of Vernalis plc in a report on Thursday, September 29th.
In other news, insider David Mackney sold 27,233 shares of the business’s stock in a transaction dated Wednesday, October 12th. The stock was sold at an average price of GBX 39 ($0.48), for a total transaction of £10,620.87 ($12,944.39). Also, insider Carol Ferguson bought 28,000 shares of the firm’s stock in a transaction dated Friday, September 30th. The shares were purchased at an average price of GBX 41 ($0.50) per share, with a total value of £11,480 ($13,991.47).
Shares of Vernalis plc (LON:VER) traded down 3.16% during mid-day trading on Wednesday, reaching GBX 38.25. 50,739 shares of the company traded hands. The company’s market capitalization is GBX 201.27 million. The firm’s 50 day moving average price is GBX 41.98 and its 200-day moving average price is GBX 44.47. Vernalis plc has a 52-week low of GBX 31.00 and a 52-week high of GBX 75.00.
Vernalis plc Company Profile
Vernalis plc is a commercial-stage pharmaceutical holding company. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. The Company has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine.
Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with MarketBeat.com's FREE daily email newsletter.